

Antiviral Therapeutics

Part II: Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015). Currently, he is writing "The Handbook of Alzheimer Disease to be published by Springer in 2022.

**November 2021 (originally published in 2007 and continuously updated and rewritten since then)
Copyright © 2021 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

13. Markets for Antivirals	5
Introduction	5
Markets according to disease.....	5
Influenza market	5
HIV/AIDS market.....	6
Hepatitis B and C markets.....	7
<i>Economics of care of hepatitis C and impact on the market</i>	<i>7</i>
Markets for diseases with low commercial significance	7
Markets according to products and approaches	8
Market values of monoclonal antibodies for viral diseases	8
Market values of vaccines for viral diseases	8
Markets for vaccines against HPV	9
Research investment and potential markets for HIV/AIDS vaccines	9
Markets for vaccines against COVID-19	9
Markets for other antiviral vaccines	9
Markets according to geographical areas.....	10
Emerging markets for antiviral therapeutics	11
Geographical distribution of HIV/AIDS market	11
Unmet needs in antivirals	11
Policies regarding conquered viral diseases	12
Future of polio vaccine.....	12
Policies concerning HPV vaccine for prevention of cervical cancer	13
<i>HPV vaccine in developing countries</i>	<i>13</i>
Future of innovative approaches.....	14
US Government support of antiviral efforts.....	15
<i>US Government support for R & D in avian influenza vaccines</i>	<i>15</i>
<i>US Government support for developing anti-bioterrorism agents.....</i>	<i>15</i>
The European Union support of antiviral research	16
<i>European Commission's research support for anti-HIV/AIDS programs</i>	<i>16</i>
<i>European Commission's support anti-influenza programs</i>	<i>17</i>
Collaboration of biotechnology companies with big pharma	18
Strategies for marketing.....	18
14. Companies	19
Introduction	19
Top companies.....	19
Profiles of pharmaceutical companies.....	20
Profiles of biopharmaceutical companies with antiviral products	36
Profiles of antiviral drug companies	127
Profiles of viral vaccine companies	155
Collaborations.....	237
15. References.....	243

Tables

Table 13-1: Worldwide market for all antiviral approaches 2020-2030	5
Table 13-2: Markets for antiviral drugs according to virus infections 2020-2030	5
Table 13-3: Markets values of all drugs for HIV/AIDS 2020-2030	6
Table 13-4: Market values of monoclonal antibodies for viral diseases 2020-2030	8
Table 13-5: Market values of vaccines for viral diseases 2020-2030	8
Table 13-6: Markets for antiviral drugs according to geographical areas 2020-2030	10
Table 13-7: Markets for antiviral vaccines according to geographical areas 2020-2030	10
Table 13-8: Emerging markets for antiviral drugs according to countries 2020-2030	11
Table 13-9: Emerging markets for antiviral vaccines according to countries 2020-2030	11
Table 14-1: Top antiviral companies	19
Table 14-2: Roche antiviral products in development	26
Table 14-3: Collaborations of antiviral companies	237

Figures

Figure 13-1: Unmet needs in antivirals	12
--	----